MCID: CHR074
MIFTS: 46

Choriocarcinoma

Categories: Cancer diseases, Fetal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Choriocarcinoma

MalaCards integrated aliases for Choriocarcinoma:

Name: Choriocarcinoma 12 74 20 36 54 44 15 17 71
Chorioepithelioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3594
KEGG 36 H00028
MeSH 44 D002822
NCIt 50 C2948
SNOMED-CT 67 189444004
ICD10 32 C58
UMLS 71 C0008497

Summaries for Choriocarcinoma

KEGG : 36 Gestational choriocarcinoma is a highly malignant epithelial tumor that can be associated with any type of gestational event, most often a complete hydatidiform mole (CM). CM occur in about one per 1000 pregnancies, and about 5-20% of CM progress to invasive moles or choriocarcinoma. Several molecular studies have been done to establish the expression of tumor-associated proteins in choriocarcinoma. In the p53 pathway, overexpression of the p53 protein and the p53-associated protein, MDM2, have been detected. Synergistic upregulation of c-MYC, c-ERB-2, c-FMS, and BCL-2 oncoproteins have also been suggested to have an important role in the pathogenesis of choriocarcinoma. Moreover, choriocarcinomas have been shown to express increased concentrations of MMP and decreased concentrations of TIMP to help with tumor invasion and metastasis.

MalaCards based summary : Choriocarcinoma, also known as chorioepithelioma, is related to choriocarcinoma of the testis and gestational ovarian choriocarcinoma. An important gene associated with Choriocarcinoma is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Peptide hormone metabolism and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include placenta, testis and ovary, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A placenta cancer that has material basis in trophoblastic cells.

Wikipedia : 74 Choriocarcinoma is a malignant, trophoblastic cancer, usually of the placenta. It is characterized by... more...

Related Diseases for Choriocarcinoma

Diseases related to Choriocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 choriocarcinoma of the testis 32.7 CSH2 CSH1
2 gestational ovarian choriocarcinoma 32.5 CSH2 CSH1
3 choriocarcinoma of ovary 32.4 CSH2 CSH1
4 non-gestational choriocarcinoma 32.3 CSH2 CSH1
5 gestational choriocarcinoma 32.3 HLA-G H19 ENPEP CSH2 CSH1
6 non-gestational ovarian choriocarcinoma 32.2 CSH2 CSH1
7 hydatidiform mole, recurrent, 1 32.1 H19 CGB5 CGB3 CGA
8 gestational trophoblastic neoplasm 31.9 H19 CSH2 CSH1 CGB5 CGB3
9 placental site trophoblastic tumor 31.6 LNPEP CSH2 CSH1 CGB5 CGB3
10 ectopic pregnancy 31.3 CGB7 CGB5 CGB3 CGA
11 teratoma 31.2 CGB7 CGB5 CGB3 CGA
12 mixed germ cell tumor 31.1 CGB3 CGA
13 gynecomastia 31.0 CYP19A1 CGB5 CGA
14 seminoma 30.9 CGB7 CGB5 CGB3 CGA
15 nonseminomatous germ cell tumor 30.8 CGB7 CGB5
16 epithelioid trophoblastic tumor 30.8 CSH2 CSH1 CGB3
17 trophoblastic neoplasm 30.8 LNPEP HLA-G H19 CSH2 CSH1 CGB5
18 germinoma 30.5 CGB5 CGB3 CGA
19 chromosomal triplication 30.5 CGB7 CGB3
20 testicular trophoblastic tumor 30.2 CSH2 CSH1
21 triploidy 30.1 CGB7 CGA
22 down syndrome 30.0 CGB7 CGB5 CGB3 CGA
23 pre-eclampsia 29.9 MALAT1 LNPEP HLA-G H19 ERVW-1 ENPEP
24 cryptorchidism, unilateral or bilateral 29.9 CYP19A1 CYP11A1 CGB5 CGA
25 adrenal cortical carcinoma 29.8 H19 CYP19A1 CYP11A1
26 placenta disease 29.8 HLA-G CSH2 CSH1 CGB7 CGB5 CGB3
27 placental choriocarcinoma 11.4
28 pediatric cns choriocarcinoma 11.4
29 fallopian tube gestational choriocarcinoma 11.4
30 childhood choriocarcinoma of the testis 11.3
31 adult central nervous system choriocarcinoma 11.3
32 childhood choriocarcinoma of the ovary 11.3
33 pulmonary artery choriocarcinoma 11.2
34 testicular monophasic choriocarcinoma 11.2
35 gestational uterine corpus choriocarcinoma 11.2
36 uterine corpus choriocarcinoma 11.2
37 pineal region choriocarcinoma 11.2
38 primary non-gestational choriocarcinoma of ovary 11.0
39 testicular germ cell tumor 10.9
40 teratocarcinoma 10.9
41 recurrent hydatidiform mole 10.9
42 choriocarcinoma of the central nervous system 10.9
43 ovarian germ cell cancer 10.8
44 germ cells tumors 10.6
45 invasive mole 10.5
46 rare tumor 10.4
47 sacrococcygeal teratoma 10.4 CGB7 CGA
48 mixed ductal-endocrine carcinoma 10.4 CGB7 CGB3
49 patellofemoral pain syndrome 10.4 CGB7 CGB3
50 anorchia 10.4 CGB5 CGA

Graphical network of the top 20 diseases related to Choriocarcinoma:



Diseases related to Choriocarcinoma

Symptoms & Phenotypes for Choriocarcinoma

GenomeRNAi Phenotypes related to Choriocarcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.6 HLA-G
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.6 HLA-G
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.6 CGB5 CGB7
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.6 HLA-G
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.6 CGB5 CGB7
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.6 HLA-G
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.6 CGB5 CGB7
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.6 HLA-G
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.6 HLA-G
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.6 CGB5 CGB7
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.6 CGB5 CGB7
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.6 HLA-G
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.6 CGB5 CGB7

Drugs & Therapeutics for Choriocarcinoma

Drugs for Choriocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Ifosfamide Approved Phase 3 3778-73-2 3690
8
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
9
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
12
Promethazine Approved, Investigational Phase 3 60-87-7 4927
13
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
14
leucovorin Approved Phase 3 58-05-9 6006
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18 Etoposide phosphate Phase 3
19 Alkylating Agents Phase 3
20 Antimitotic Agents Phase 3
21
Isophosphamide mustard Phase 3 100427
22 Adjuvants, Immunologic Phase 3
23 Albumin-Bound Paclitaxel Phase 3
24 Tubulin Modulators Phase 3
25 Keratolytic Agents Phase 3
26 Podophyllotoxin Phase 3 518-28-5
27 Histamine H2 Antagonists Phase 3
28 Micronutrients Phase 3
29 Nutrients Phase 3
30 Immunosuppressive Agents Phase 3
31 Trace Elements Phase 3
32 Protective Agents Phase 3
33 Vitamin B Complex Phase 3
34 Antimetabolites Phase 3
35 Vitamins Phase 3
36 Folate Phase 3
37 Vitamin B9 Phase 3
38 Immunologic Factors Phase 3
39 Calcium, Dietary Phase 3
40 Antidotes Phase 3
41 Hematinics Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Folic Acid Antagonists Phase 3
44 Anti-Bacterial Agents Phase 3
45 Anti-Infective Agents Phase 3
46 Antirheumatic Agents Phase 3
47 Dermatologic Agents Phase 3
48 Cactinomycin Phase 3
49
Calcium Nutraceutical Phase 3 7440-70-2 271
50
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
2 A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
3 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors Recruiting NCT03067181 Phase 3 Bleomycin;Carboplatin;Cisplatin;Etoposide;Etoposide Phosphate
4 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Recruiting NCT02375204 Phase 3 paclitaxel;ifosfamide;cisplatin;pegylated G-CSF;G-CSF;carboplatin;etoposide phosphate
5 A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
6 Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma Completed NCT02396511 Phase 2
7 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
8 A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor Completed NCT00190918 Phase 2 Pemetrexed
9 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
10 A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated NCT02664961 Phase 2 TRC105;Bevacizumab
11 A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors Completed NCT00281944 Phase 1 oxaliplatin;fluorouracil;leucovorin calcium
12 A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors Completed NCT00929903 Phase 1 pazopanib hydrochloride
13 A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
14 A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors Completed NCT00387920 Phase 1 sunitinib malate
15 CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00060372 Phase 1 ipilimumab;therapeutic allogeneic lymphocytes
16 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas Completed NCT00994500 Phase 1 vorinostat;bortezomib
17 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
18 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Persistent Gestational Trophoblastic Tumors Using Atomic Force Microscopy and Dual Polarisation Interferometry Unknown status NCT00294177
19 A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT01080521
20 Molecular Epidemiology of Pediatric Germ Cell Tumors Completed NCT01434355
21 Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer Completed NCT03426865 Axumin PET scan
22 A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms Recruiting NCT01267851
23 A Prospective,Multicenter,Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia Recruiting NCT04562558 Methotrexate;Leucovorin;Dactinomycin

Search NIH Clinical Center for Choriocarcinoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Chlorambucil
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: choriocarcinoma

Genetic Tests for Choriocarcinoma

Anatomical Context for Choriocarcinoma

MalaCards organs/tissues related to Choriocarcinoma:

40
Placenta, Testis, Ovary, Uterus, Thyroid, Pineal, Cervix

Publications for Choriocarcinoma

Articles related to Choriocarcinoma:

(show top 50) (show all 6520)
# Title Authors PMID Year
1
Nitrofurantoin transport by placental choriocarcinoma JAr cells: involvement of BCRP, OATP2B1 and other MDR transporters. 54 61
19924425 2010
2
Involvement of Heparanase in early pregnancy losses. 61 54
20031192 2010
3
Testicular choriocarcinoma metastatic to skin and multiple organs. Two case reports and review of literature. 54 61
19469863 2010
4
Role of regulatory and angiogenic cytokines in invasion of trophoblastic cells. 61 54
20047586 2010
5
hGH-V gene expression and promoter activity under glucose and 5-azacytidine (5azaC) effects. 54 61
20005926 2010
6
Involvement of transcription factor NR2F2 in human trophoblast differentiation. 54 61
20195529 2010
7
Pulmonary metastases revealing choriocarcinoma. 61 54
20415215 2010
8
Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. 54 61
20043267 2010
9
p53 Mediates epidermal growth factor (EGF) induction of MMP-2 transcription and trophoblast invasion. 61 54
19853299 2009
10
Inhibiton of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. 61 54
19900702 2009
11
CD9 regulates transcription factor GCM1 and ERVWE1 expression through the cAMP/protein kinase A signaling pathway. 54 61
19692500 2009
12
Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion. 61 54
19939245 2009
13
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. 61 54
19805167 2009
14
Human chorionic gonadotropin tests. 54 61
19817556 2009
15
Interleukin-11 increases invasiveness of JEG-3 choriocarcinoma cells by modulating STAT3 expression. 61 54
19716605 2009
16
Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines. 61 54
19758196 2009
17
Docosahexaenoic acid induces adipose differentiation-related protein through activation of retinoid x receptor in human choriocarcinoma BeWo cells. 54 61
19571381 2009
18
MyD88 and TRIF mediate the cyclic adenosine monophosphate (cAMP) induced corticotropin releasing hormone (CRH) expression in JEG3 choriocarcinoma cell line. 54 61
19615077 2009
19
Endometrial carcinoma with choriocarcinomatous differentiation: a case report and review of the literature. 61 54
19232701 2009
20
An aggressive course of de novo ulcerative colitis after renal transplantation: colonic adenocarcinoma with choriocarcinomatous differentiation. 54 61
19927772 2009
21
Human chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early human pregnancy. 54 61
19380797 2009
22
Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. 61 54
19426551 2009
23
Immunohistochemical studies of trophoblastic tumors. 61 54
19145204 2009
24
Metal transcription factor-1 is involved in hypoxia-dependent regulation of placenta growth factor in trophoblast-derived cells. 54 61
19022893 2009
25
Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway. 61 54
19181434 2009
26
Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells. 61 54
19260856 2009
27
Interactions between riluzole and ABCG2/BCRP transporter. 54 61
19146924 2009
28
Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. 54 61
19022235 2009
29
Effect of progesterone on HLA-E gene expression in JEG-3 choriocarcinoma cell line. 61 54
19239424 2009
30
Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. 61 54
19133314 2009
31
Human chorionic gonadotropin and associated molecules. 61 54
19099349 2009
32
Prenatal findings in a case of massive fetomaternal hemorrhage associated with intraplacental choriocarcinoma. 54 61
19293586 2009
33
Up-regulation of placental leptin by human chorionic gonadotropin. 61 54
18787032 2009
34
Leptin prevents apoptosis of trophoblastic cells by activation of MAPK pathway. 61 54
18619412 2008
35
Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. 54 61
17975728 2008
36
Expression of glypican 3 in ovarian and extragonadal germ cell tumors. 61 54
18628091 2008
37
Effect of Ad-TIMP3 on biologic behavior of choriocarcinoma cells in vitro. 61 54
18773626 2008
38
Immune cell profiling in intraplacental and postmolar choriocarcinomas. 61 54
18773618 2008
39
A novel mechanism of TGFbeta-induced actin reorganization mediated by Smad proteins and Rho GTPases. 54 61
18631173 2008
40
Endocrine disruption induced by organotin compounds; organotins function as a powerful agonist for nuclear receptors rather than an aromatase inhibitor. 61 54
18670157 2008
41
Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. 61 54
18066564 2008
42
Endoglin (CD105) expression is regulated by the liver X receptor alpha (NR1H3) in human trophoblast cell line JAR. 61 54
18276933 2008
43
[Effects on human leukocyte antigen-G on proliferation and invasion of JEG-3 cell line]. 54 61
19035141 2008
44
Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation. 61 54
18362896 2008
45
Stimuli through Toll-like receptor (TLR) 3 and 9 affect human chorionic gonadotropin (hCG) production in a choriocarcinoma cell line. 54 61
18412774 2008
46
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. 61 54
18042733 2008
47
Placental site trophoblastic tumor. 61 54
17701427 2008
48
Primary ovarian choriocarcinoma mimicking ectopic pregnancy managed with laparoscopy -- case report. 54 61
18459557 2008
49
STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. 54 61
19079545 2008
50
Involvement of RelA-associated inhibitor in regulation of trophoblast differentiation via interaction with transcriptional factor specificity protein-1. 54 61
17872376 2007

Variations for Choriocarcinoma

Expression for Choriocarcinoma

Search GEO for disease gene expression data for Choriocarcinoma.

Pathways for Choriocarcinoma

GO Terms for Choriocarcinoma

Cellular components related to Choriocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 HLA-G GH2 CSH2 CSH1 CGB7 CGB5
2 extracellular region GO:0005576 9.32 MGAT4A LNPEP HLA-G GH2 CSH2 CSH1
3 endosome lumen GO:0031904 9.16 GH2 CSH1

Biological processes related to Choriocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.11 LNPEP GH2 ENPEP CSH2 CSH1 CGB7
2 cell-cell signaling GO:0007267 9.77 LNPEP ENPEP CGB7 CGB5 CGB3
3 response to nutrient levels GO:0031667 9.69 GH2 CSH2 CSH1
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 GH2 CSH2 CSH1
5 hormone-mediated signaling pathway GO:0009755 9.61 CGB7 CGB5 CGB3
6 positive regulation of JAK-STAT cascade GO:0046427 9.58 GH2 CSH2 CSH1
7 sterol metabolic process GO:0016125 9.55 CYP19A1 CYP11A1
8 peptide catabolic process GO:0043171 9.54 LNPEP ENPEP
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.52 GH2 CSH1
10 animal organ development GO:0048513 9.5 GH2 CSH2 CSH1
11 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 LNPEP HLA-G
12 female gamete generation GO:0007292 9.43 CGB7 CGB5 CGB3
13 peptide hormone processing GO:0016486 9.33 CGB5 CGB3 CGA
14 growth hormone receptor signaling pathway GO:0060396 9.13 GH2 CSH2 CSH1
15 positive regulation of growth GO:0045927 8.8 GH2 CSH2 CSH1

Molecular functions related to Choriocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 GH2 CSH2 CSH1 CGB7 CGB5 CGB3
2 metalloaminopeptidase activity GO:0070006 9.16 LNPEP ENPEP
3 growth hormone receptor binding GO:0005131 9.13 GH2 CSH2 CSH1

Sources for Choriocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....